Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12920239rdf:typepubmed:Citationlld:pubmed
pubmed-article:12920239lifeskim:mentionsumls-concept:C1522424lld:lifeskim
pubmed-article:12920239lifeskim:mentionsumls-concept:C0026336lld:lifeskim
pubmed-article:12920239lifeskim:mentionsumls-concept:C0126732lld:lifeskim
pubmed-article:12920239lifeskim:mentionsumls-concept:C1522564lld:lifeskim
pubmed-article:12920239lifeskim:mentionsumls-concept:C0021308lld:lifeskim
pubmed-article:12920239lifeskim:mentionsumls-concept:C0035126lld:lifeskim
pubmed-article:12920239lifeskim:mentionsumls-concept:C1334877lld:lifeskim
pubmed-article:12920239lifeskim:mentionsumls-concept:C0456389lld:lifeskim
pubmed-article:12920239lifeskim:mentionsumls-concept:C1517499lld:lifeskim
pubmed-article:12920239lifeskim:mentionsumls-concept:C2349209lld:lifeskim
pubmed-article:12920239lifeskim:mentionsumls-concept:C1549649lld:lifeskim
pubmed-article:12920239pubmed:issue8lld:pubmed
pubmed-article:12920239pubmed:dateCreated2003-8-15lld:pubmed
pubmed-article:12920239pubmed:abstractTextNuclear factor-kappaB (NF-kappaB) plays a central role in myocardial ischemia-reperfusion (MI/R) injury. The inhibitory protein IkappaBalpha prevents its activation. We investigated the effects of adeno-associated viral vector-mediated IkappaBalpha gene transfer in MI/R injury. Male C57BL/6 mice were randomized to receive a recombinant adeno-associated virus (rAAV) encoding the gene for the NF-kappaB inhibitory protein IkappaBalpha (rAAV- IkappaBalpha) or the beta-galactosidase gene (a control and inert gene; rAAV-LacZ), both at a dose of 10(11) copies. Four weeks later anesthetized animals were subjected to total occlusion (45 minutes) of the left main coronary artery followed by 5 hours of reperfusion. MI/R produced a wide infarct size (IF/area-at-risk = 56 +/- 8%; IF/left ventricle = 44 +/- 5%) and tissue neutrophil infiltration, studied by means of elastase activity (area-at-risk = 2.5 +/- 0.4 micro g/gm tissue; infarct area = 2.9 +/- 0.6 micro g/gm tissue). Furthermore MI/R caused peak message for intercellular adhesion molecule-1 (ICAM-1) in the area-at-risk at 3 hours of reperfusion (1.2 +/- 0.4 relative amount of cardiac ICAM-1 mRNA). NF-kappaB activation was evident at 0.5 hours of reperfusion and reached its maximum increase at 2 hours of reperfusion. rAAV-IkappaBalpha injection reduced infarct size (IF/area-at-risk = 19 +/- 3%; IF/left ventricle = 10 +/- 2%; p < 0.001), blocked NF-kappaB activation, diminished cardiac ICAM-1 expression (0.4 +/- 0.02 relative amount of cardiac ICAM-1 mRNA; p < 0.001), and blunted leukocyte accumulation (area-at-risk = 0.6 +/- 0.05 micro g/gm tissue; infarct area = 0.4 +/- 0.02 micro g/gm tissue; p < 0.001). Our data indicate that rAAV-IkappaBalpha may be useful for MI/R gene therapy.lld:pubmed
pubmed-article:12920239pubmed:languageenglld:pubmed
pubmed-article:12920239pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12920239pubmed:citationSubsetIMlld:pubmed
pubmed-article:12920239pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12920239pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12920239pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12920239pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12920239pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12920239pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12920239pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12920239pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12920239pubmed:statusMEDLINElld:pubmed
pubmed-article:12920239pubmed:monthAuglld:pubmed
pubmed-article:12920239pubmed:issn0023-6837lld:pubmed
pubmed-article:12920239pubmed:authorpubmed-author:AltavillaDome...lld:pubmed
pubmed-article:12920239pubmed:authorpubmed-author:SquadritoGiov...lld:pubmed
pubmed-article:12920239pubmed:authorpubmed-author:GaleanoMariar...lld:pubmed
pubmed-article:12920239pubmed:authorpubmed-author:SquadritoFran...lld:pubmed
pubmed-article:12920239pubmed:authorpubmed-author:GiaccaMauroMlld:pubmed
pubmed-article:12920239pubmed:authorpubmed-author:MinutoliLette...lld:pubmed
pubmed-article:12920239pubmed:authorpubmed-author:DeodatoBarbar...lld:pubmed
pubmed-article:12920239pubmed:authorpubmed-author:SeminaraPaolo...lld:pubmed
pubmed-article:12920239pubmed:authorpubmed-author:PassanitiMari...lld:pubmed
pubmed-article:12920239pubmed:authorpubmed-author:MariniHerbert...lld:pubmed
pubmed-article:12920239pubmed:authorpubmed-author:VenutiFrances...lld:pubmed
pubmed-article:12920239pubmed:authorpubmed-author:MariniRolando...lld:pubmed
pubmed-article:12920239pubmed:authorpubmed-author:AdamoElena...lld:pubmed
pubmed-article:12920239pubmed:authorpubmed-author:BellomoMariaMlld:pubmed
pubmed-article:12920239pubmed:issnTypePrintlld:pubmed
pubmed-article:12920239pubmed:volume83lld:pubmed
pubmed-article:12920239pubmed:ownerNLMlld:pubmed
pubmed-article:12920239pubmed:authorsCompleteYlld:pubmed
pubmed-article:12920239pubmed:pagination1097-104lld:pubmed
pubmed-article:12920239pubmed:dateRevised2005-11-17lld:pubmed
pubmed-article:12920239pubmed:meshHeadingpubmed-meshheading:12920239...lld:pubmed
pubmed-article:12920239pubmed:meshHeadingpubmed-meshheading:12920239...lld:pubmed
pubmed-article:12920239pubmed:meshHeadingpubmed-meshheading:12920239...lld:pubmed
pubmed-article:12920239pubmed:meshHeadingpubmed-meshheading:12920239...lld:pubmed
pubmed-article:12920239pubmed:meshHeadingpubmed-meshheading:12920239...lld:pubmed
pubmed-article:12920239pubmed:meshHeadingpubmed-meshheading:12920239...lld:pubmed
pubmed-article:12920239pubmed:meshHeadingpubmed-meshheading:12920239...lld:pubmed
pubmed-article:12920239pubmed:meshHeadingpubmed-meshheading:12920239...lld:pubmed
pubmed-article:12920239pubmed:meshHeadingpubmed-meshheading:12920239...lld:pubmed
pubmed-article:12920239pubmed:meshHeadingpubmed-meshheading:12920239...lld:pubmed
pubmed-article:12920239pubmed:meshHeadingpubmed-meshheading:12920239...lld:pubmed
pubmed-article:12920239pubmed:meshHeadingpubmed-meshheading:12920239...lld:pubmed
pubmed-article:12920239pubmed:meshHeadingpubmed-meshheading:12920239...lld:pubmed
pubmed-article:12920239pubmed:meshHeadingpubmed-meshheading:12920239...lld:pubmed
pubmed-article:12920239pubmed:meshHeadingpubmed-meshheading:12920239...lld:pubmed
pubmed-article:12920239pubmed:meshHeadingpubmed-meshheading:12920239...lld:pubmed
pubmed-article:12920239pubmed:meshHeadingpubmed-meshheading:12920239...lld:pubmed
pubmed-article:12920239pubmed:meshHeadingpubmed-meshheading:12920239...lld:pubmed
pubmed-article:12920239pubmed:meshHeadingpubmed-meshheading:12920239...lld:pubmed
pubmed-article:12920239pubmed:year2003lld:pubmed
pubmed-article:12920239pubmed:articleTitleGene transfer of IkappaBalpha limits infarct size in a mouse model of myocardial ischemia-reperfusion injury.lld:pubmed
pubmed-article:12920239pubmed:affiliationDepartment of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy. Francesco.Squadrito@unime.itlld:pubmed
pubmed-article:12920239pubmed:publicationTypeJournal Articlelld:pubmed
entrez-gene:18035entrezgene:pubmedpubmed-article:12920239lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:12920239lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12920239lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12920239lld:pubmed